Latest Updates in Lung Cancer Treatment
Non-Small Cell Lung Cancer (NSCLC)
First-Line Therapy for Metastatic Disease
For patients with actionable molecular alterations, targeted therapy has become the standard of care, with multiple new agents approved since 2018 that significantly extend survival. 1
Patients with EGFR Mutations
- Osimertinib, afatinib, erlotinib, or gefitinib are recommended for first-line treatment 1
- Osimertinib demonstrates high activity against CNS disease 1
- Major advancement: Adjuvant osimertinib is now recommended (category 1) for completely resected stage IIB-IIIA and high-risk stage IB-IIA EGFR-mutated NSCLC after adjuvant chemotherapy or for patients ineligible for platinum chemotherapy 1, 2
Patients with ALK Rearrangements
- Lorlatinib is now a preferred first-line option (category 1), representing a significant update 1
- Other preferred first-line options include alectinib (category 1), brigatinib (category 1), and ceritinib 1
- Alectinib shows longer PFS and lower toxicity than crizotinib with superior CNS activity 1
- Brigatinib demonstrates longer PFS than crizotinib with excellent CNS penetration 1
Patients with ROS1 Rearrangements
- Crizotinib remains the preferred agent (category 1) 1
- Ceritinib is recommended as category 2A 1
- Entrectinib may be superior for patients with brain metastases 1
Patients with BRAF V600E Mutations
- Dabrafenib/trametinib combination should be used in first or second line 1
Emerging Targeted Therapies (Major Updates)
- Capmatinib and tepotinib are approved for MET exon 14 skipping mutations 1, 3
- Selpercatinib and pralsetinib are approved for RET rearrangements 1
- Sotorasib and adagrasib target KRAS G12C mutations (∼15% of NSCLC), approved as second-line agents; adagrasib shows benefit in first-line combination with pembrolizumab 3
- Amivantamab is approved for EGFR exon 20 insertion mutations after platinum-based chemotherapy 3
- Trastuzumab deruxtecan is approved for HER2-overexpressing NSCLC (IHC 3+) after platinum-based chemotherapy 1, 3
- Fam-trastuzumab deruxtecan is recommended for HER2 mutations 1
Immunotherapy Updates for Patients Without Driver Alterations
First-Line Immunotherapy
- Pembrolizumab monotherapy (category 1) for PD-L1 ≥50% 1
- Atezolizumab monotherapy (category 1) for PD-L1 ≥50% (upgraded from category 2A) 1
- Nivolumab plus ipilimumab (category 1) for PD-L1 ≥1% (upgraded from category 2A) 1
- Pembrolizumab/carboplatin/pemetrexed (category 1) for nonsquamous NSCLC (upgraded from category 2A) 1
- Atezolizumab/carboplatin/paclitaxel/bevacizumab (category 1) for metastatic nonsquamous NSCLC 1
- Pembrolizumab/carboplatin/paclitaxel (category 2A) for squamous cell carcinoma 1
- Durvalumab plus tremelimumab plus platinum-based chemotherapy is an option 1
Consolidation Immunotherapy
- Durvalumab consolidation (category 1) after concurrent chemoradiotherapy for unresectable stage III NSCLC without progression 1
- New recommendation: Durvalumab (category 2A) for unresectable stage II NSCLC after definitive concurrent chemoradiotherapy 1
Second-Line and Subsequent Therapy
After Immunotherapy Without Chemotherapy
- Platinum doublet chemotherapy is recommended 1
After Platinum-Based Chemotherapy
- Docetaxel with or without ramucirumab is recommended 1
- Nivolumab (category 1), pembrolizumab (category 1), and atezolizumab (category 1) are preferred options with improved survival and fewer adverse events compared to cytotoxic chemotherapy 1
- Pemetrexed or gemcitabine may be offered 1
- Datopotamab deruxtecan shows improved PFS compared to docetaxel, particularly in non-squamous histology 1
Important Testing Updates
- Routine molecular biomarker testing should be considered in all patients with metastatic NSCLC squamous cell carcinoma (previously limited to adenocarcinoma) 1
- EGFR mutation testing can be considered for completely resected stage IB-IIIA NSCLC 1
- Tumor mutational burden (TMB) was removed as a biomarker due to lack of clinical utility, variable measurements, and insufficient data 1
- Testing should include: EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF V600E, MET exon 14 skipping, NTRK fusions, RET rearrangements, KRAS G12C, HER2 mutations, and PD-L1 expression 1
Small Cell Lung Cancer (SCLC)
Limited-Stage SCLC
The most significant update is consolidation durvalumab after concurrent chemoradiotherapy, which represents the first major advance in limited-stage SCLC in decades. 1
- Standard treatment: Cisplatin or carboplatin plus etoposide × 4 cycles with concurrent thoracic radiotherapy 1
- Major update: Consolidation durvalumab after concurrent chemoradiotherapy for patients without disease progression (ECOG PS 0-1) 1
- For resected disease: Adjuvant cisplatin or carboplatin plus etoposide 1
Extensive-Stage SCLC
First-Line Therapy
- Carboplatin or cisplatin plus etoposide plus immunotherapy (atezolizumab or durvalumab) for ECOG PS 0-2 1
- This combination represents a major advance over chemotherapy alone 4
- For ECOG PS 3-4 due to SCLC: Initial carboplatin plus etoposide × 4 cycles; consider maintenance immunotherapy if PS improves 1
Second-Line Therapy
- Lurbinectedin has conditional FDA approval for relapsed ES-SCLC 5
- Topotecan remains an option for platinum-sensitive disease 5
- Trilaciclib (CDK 4/6 inhibitor) is approved as supportive care prior to chemotherapy to reduce myelosuppression 5
Key Considerations
- SCLC is characterized by rapid growth, high metastatic capacity, almost universal TP53 and RB1 inactivation, and high mutation burden 4
- Despite initial chemosensitivity, drug resistance develops rapidly 4
- Emerging molecular subtype classifications may define unique therapeutic vulnerabilities 4
Critical Practice Points
Common Pitfalls to Avoid
- Do not use erlotinib for patients without EGFR mutations in subsequent therapy for nonsquamous NSCLC—this recommendation was deleted based on the IUNO trial showing no benefit 1
- Avoid bevacizumab in squamous cell carcinoma, significant hemoptysis, ECOG PS >1, or uncontrolled hypertension 1
- Do not delay molecular testing—it should be completed before initiating first-line therapy for metastatic disease 1
- Patients with EGFR mutations or ALK rearrangements have low response rates to PD-1/PD-L1 inhibitors (3.6% vs 23% in wild-type) 1